Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Eli Lilly invents and sells prescription medicines for diabetes, obesity, cancer, and other serious diseases.
Eli Lilly is a drug company. It discovers, tests, and sells prescription medicines, and its biggest business today is a family of drugs that treat diabetes and obesity. Its headquarters are in Indianapolis, Indiana, a city it has called home since the 1870s. Doctors prescribe its medicines; patients take them; insurance companies and governments foot much of the bill. That is the whole machine in one sentence.
The drug everyone knows is tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss. It is a once-weekly injection that helps control blood sugar and makes people feel full, so they eat less and lose weight. Demand exploded after launch, and Lilly has been racing to build enough factories to make it. The drug is expected to become one of the best-selling medicines in history. Lilly also sells older diabetes drugs, cancer treatments, and medicines for migraine and Alzheimer's, but the weight-loss wave is what moves the stock. Here is the brutal truth about this business: making a pill or a shot is cheap. Finding one that works, proving it in huge trials, and getting regulators to approve it is brutally expensive and slow. Most experiments fail. The winners have to pay for all the losers, which is why new drugs cost so much and why patents matter so much. A patent gives the company years of exclusive sales, then generics copy it and prices collapse. Lilly's whole value rests on staying ahead of that cliff with new drugs.
In 1876, Colonel Eli Lilly, a 38-year-old pharmaceutical chemist and Civil War veteran, founded the company in Indianapolis. He was fed up with the poorly made, often useless medicines of his day. So he built Lilly around a simple promise: make high-quality medicines based on the best science, and sell them through doctors rather than through hucksters. That idea, that the medicine itself should be good, became the company's foundation.
In 1923, Lilly introduced the world's first commercially available insulin, working with University of Toronto researchers Frederick Banting and Charles Best. Diabetes had been a fatal disease with no effective treatment. Lilly became the first large-scale producer of insulin, and suddenly a death sentence had a lifeline.
Lilly was among the first companies to develop a way to mass-produce penicillin-G, the first globally widespread antibiotic. This was the start of a long, sustained effort against infectious diseases.
In 1952, Lilly became a publicly traded company, opening its ownership to outside investors.
In 1982, Lilly introduced Humulin, insulin identical to what the human body makes. It was the world's first human-health-care product created using recombinant DNA technology. The insulin business that began in 1923 had just leapt into the genetic age.
In 1986, Lilly launched Prozac, the first major introduction in a new class of drugs for clinical depression.
David Ricks took over as CEO in 2017 from the retiring John Lechleiter, and he shook things up: he merged Europe and Emerging Markets into one international division to make Lilly leaner ahead of acquisitions. The changes followed the high-profile failure of an Alzheimer's candidate called solanezumab and came just ahead of patent expiries on two big drugs. Lilly was slimming down for what came next.
In 2019, Lilly made its largest acquisition to date, buying Loxo Oncology to broaden treatment options for cancer patients. The roughly $8 billion deal boosted a cancer business that had been thin for years. Loxo's team, led by CEO Josh Bilenker, was later put in charge of Lilly's early cancer drug development, renamed Loxo Oncology at Lilly.
Tirzepatide was approved in 2022, first for diabetes under the name Mounjaro, with a weight-loss version called Zepbound following in late 2023. It was the first GIP/GLP-1 dual-target receptor agonist, and head-to-head data showed better weight loss than single-target semaglutide. Sales exploded, from over $5 billion in 2023 to over $16.5 billion in 2024. Lilly had found its biggest prize yet.
In August 2024, Lilly's stock peaked at $967 per share, valuing the company above $910 billion, the closest any drugmaker had come to $1 trillion. Then weak sales, missed expectations for Zepbound and Mounjaro, and tariff threats drove shares down 21% from the record. In May, CVS Health dropped Zepbound from its preferred list in favor of Novo's Wegovy, and the stock fell 12% in a day, its biggest drop since October 2008.
Booming demand for Mounjaro and Zepbound drove third-quarter 2026 revenue up 38.6% to $24.4 billion, and Lilly raised its 2026 revenue forecast to $91–92 billion. Mounjaro quarterly sales reached $10.72 billion and Zepbound $5.35 billion, and the stock hit a record high. The lead over Novo Nordisk pushed Lilly to a $1.2 trillion market valuation, making it the world's most valuable healthcare company.
Lilly spent decades as a solid but unexciting company. Then the weight-loss boom turned it into one of the most valuable companies on earth, and it is spending accordingly — billions on new manufacturing plants in the US and Europe to keep up with demand, plus deals to buy smaller biotech firms. It also pays a dividend that it has raised for well over a century, which it can afford because the drugs throw off enormous cash. The risk is simple: a competitor's pill, an insurance company refusing to pay, or a side-effect scare could cool the boom fast.
Saved answer · last researched 22 Oct 2026